Mikael Landén1,2, Henrik Larsson3,4, Paul Lichtenstein3, Johan Westin5, Jie Song3. 1. Section of Psychiatry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Blå Stråket 15, 413 45, Gothenburg, Sweden. mikael.landen@gu.se. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. mikael.landen@gu.se. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 4. Department of Medical Sciences, Örebro University, Örebro, Sweden. 5. Department of Infectious Diseases, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Abstract
BACKGROUND: In vitro studies have demonstrated that lithium has antiviral properties, but evidence from human studies is scarce. Lithium is used as a mood stabilizer to treat patients with bipolar disorder. Here, the aim was to investigate the association between lithium use and the risk of respiratory infections in patients with bipolar disorder. To rule out the possibility that a potential association could be due to lithium's effect on psychiatric symptoms, we also studied the effect of valproate, which is an alternative to lithium used to prevent mood episodes in bipolar disorder. METHOD: We followed 51,509 individuals diagnosed with bipolar disorder in the Swedish Patient register 2005-2013. We applied a within-individual design using stratified Cox regression to estimate the hazard ratios (HRs) of respiratory infections during treated periods compared with untreated periods. RESULTS: During follow-up, 5,760 respiratory infections were documented in the Swedish Patient Register. The incidence rate was 28% lower during lithium treatment (HR 0.73, 95% CI 0.61-0.86) and 35% higher during valproate treatment (HR 1.35, 95% CI 1.06-1.73) compared with periods off treatment. CONCLUSIONS: This study provides real-world evidence that lithium is associated with decreased risk for respiratory infections and suggests that the repurposing potential of lithium for potential antiviral or antibacterial effects is worthy of investigation.
BACKGROUND: In vitro studies have demonstrated that lithium has antiviral properties, but evidence from human studies is scarce. Lithium is used as a mood stabilizer to treat patients with bipolar disorder. Here, the aim was to investigate the association between lithium use and the risk of respiratory infections in patients with bipolar disorder. To rule out the possibility that a potential association could be due to lithium's effect on psychiatric symptoms, we also studied the effect of valproate, which is an alternative to lithium used to prevent mood episodes in bipolar disorder. METHOD: We followed 51,509 individuals diagnosed with bipolar disorder in the Swedish Patient register 2005-2013. We applied a within-individual design using stratified Cox regression to estimate the hazard ratios (HRs) of respiratory infections during treated periods compared with untreated periods. RESULTS: During follow-up, 5,760 respiratory infections were documented in the Swedish Patient Register. The incidence rate was 28% lower during lithium treatment (HR 0.73, 95% CI 0.61-0.86) and 35% higher during valproate treatment (HR 1.35, 95% CI 1.06-1.73) compared with periods off treatment. CONCLUSIONS: This study provides real-world evidence that lithium is associated with decreased risk for respiratory infections and suggests that the repurposing potential of lithium for potential antiviral or antibacterial effects is worthy of investigation.
Authors: Livia J De Picker; Marion Leboyer; John R Geddes; Manuel Morrens; Paul J Harrison; Maxime Taquet Journal: Br J Psychiatry Date: 2022-07 Impact factor: 10.671
Authors: Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux Journal: Front Psychiatry Date: 2022-01-13 Impact factor: 4.157
Authors: Xiaolei Liu; Anurag Verma; Gustavo Garcia; Holly Ramage; Anastasia Lucas; Rebecca L Myers; Jacob J Michaelson; William Coryell; Arvind Kumar; Alexander W Charney; Marcelo G Kazanietz; Daniel J Rader; Marylyn D Ritchie; Wade H Berrettini; David C Schultz; Sara Cherry; Robert Damoiseaux; Vaithilingaraja Arumugaswami; Peter S Klein Journal: Proc Natl Acad Sci U S A Date: 2021-09-30 Impact factor: 12.779
Authors: Felicia Ceban; Danica Nogo; Isidro P Carvalho; Yena Lee; Flora Nasri; Jiaqi Xiong; Leanna M W Lui; Mehala Subramaniapillai; Hartej Gill; Rene N Liu; Prianca Joseph; Kayla M Teopiz; Bing Cao; Rodrigo B Mansur; Kangguang Lin; Joshua D Rosenblat; Roger C Ho; Roger S McIntyre Journal: JAMA Psychiatry Date: 2021-10-01 Impact factor: 25.911
Authors: Eva Z Reininghaus; Mirko Manchia; Nina Dalkner; Nina Bonkat; Alessio Squassina; Isabel Hodl; Eduard Vieta; Andreas Reif; Tomas Hajek; Mikael Landén; Christoph U Correll; Jan Scott; Bruno Etain; Marcella Rietschel; Veerle Bergink; Monica Martinez-Cengotitabengoa; Lars Vedel Kessing; Andrea Fagiolini; Michael Bauer; Guy Goodwin; Ana Gonzalez-Pinto; Ralph W Kupka; Thomas G Schulze; Trine V Lagerberg; Ayşegül Yildiz; Chantal Henry; Gunnar Morken; Phillip Ritter; René Ernst Nieslen; Rasmus W Licht; Andreas Bechdolf; Ole A Andreassen; Frederike Tabea Fellendorf Journal: Eur Neuropsychopharmacol Date: 2021-09-10 Impact factor: 4.600